We are live on ! Find out more
AXSM icon

Axsome Therapeutics
AXSM

231 hedge funds and large institutions have $2.61B invested in Axsome Therapeutics in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 90 increasing their positions, 54 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 16

75% more call options, than puts

Call options by funds: $106M | Put options by funds: $60.5M

67% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 54

33% more capital invested

Capital invested by funds: $1.97B → $2.61B (+$647M)

17% more funds holding

Funds holding: 197 → 231 (+34)

4.83% more ownership

Funds ownership: 73.31% → 78.14% (+4.8%)

11% less funds holding in top 10

Funds holding in top 10: 9 → 8 (-1)

Holders
231
Holders Change
+34
Holders Change %
+17.26%
% of All Funds
3.63%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
50
Increased
90
Reduced
54
Closed
16
Calls
$106M
Puts
$60.5M
Net Calls
+$45.1M
Net Calls Change
+$22.7M

Top Buyers

1
RCM
RA Capital Management
Massachusetts
+$73.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$56.4M
3
RI
RTW Investments
New York
+$37.1M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$34M
5
DTC
Deep Track Capital
Connecticut
+$28.3M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$51.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$44.7M
3
Holocene Advisors
Holocene Advisors
New York
-$32.6M
4
Millennium Management
Millennium Management
New York
-$22.4M
5
WP
Woodline Partners
California
-$9.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
101
Soleus Capital Management
Connecticut
$1.79M +$310K +4,200 +20%
Russell Investments Group
102
Russell Investments Group
United Kingdom
$1.77M +$1.81M +24,578 +117,038%
SCA
103
Sassicaia Capital Advisers
New York
$1.72M +$1.77M +24,000 New
New York State Common Retirement Fund
104
New York State Common Retirement Fund
New York
$1.69M -$132K -1,796 -7%
UBS AM
105
UBS AM
Illinois
$1.53M – – –
T. Rowe Price Associates
106
T. Rowe Price Associates
Maryland
$1.47M +$312K +4,227 +26%
CIBC Private Wealth Group
107
CIBC Private Wealth Group
Georgia
$1.47M +$280K +3,795 +23%
BC
108
Brookfield Corp
Ontario, Canada
$1.4M -$891K -12,074 -38%
MWM
109
Meridian Wealth Management
Kentucky
$1.36M +$184K +2,500 +15%
RJFSA
110
Raymond James Financial Services Advisors
Florida
$1.33M +$129K +1,744 +10%
EI
111
EAM Investors
California
$1.3M +$1.34M +18,102 New
DIA
112
Dana Investment Advisors
Wisconsin
$1.27M -$90.7K -1,230 -7%
FAM
113
Fred Alger Management
New York
$1.25M +$1.29M +17,422 New
MIM
114
MetLife Investment Management
New Jersey
$1.24M +$23.7K +321 +2%
PRC
115
Pearl River Capital
Michigan
$1.18M +$499K +6,766 +70%
HIS
116
Harvest Investment Services
Illinois
$1.17M +$1.21M +16,349 New
JGC
117
J. Goldman & Co
New York
$1.15M -$3.42M -46,405 -74%
AIG
118
American International Group
New York
$1.14M +$27.1K +368 +2%
PAMP
119
Polar Asset Management Partners
Ontario, Canada
$1.11M +$1.14M +15,465 New
QIM
120
Quantitative Investment Management
Virginia
$1.1M +$1.13M +15,300 New
Mirae Asset Global Investments
121
Mirae Asset Global Investments
South Korea
$1.1M +$24.3K +329 +2%
BMSSC
122
B. Metzler seel. Sohn & Co
Germany
$1.09M +$595K +8,059 +113%
MCM
123
Moore Capital Management
New York
$1.08M +$1.11M +15,000 New
UBS Group
124
UBS Group
Switzerland
$1.05M -$125K -1,692 -10%
Simplex Trading
125
Simplex Trading
Illinois
$1.03M +$1.02M +13,781 +2,461%
3 4
5
6 7

AXSM Hedge Fund Activity: Q2 2023 in Review

231 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2023, worth a combined $2.61B — up 33% from $1.97B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new AXSM positions and 16 closed out — a net gain of 34 holders — while 90 added to existing stakes and 54 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $73.8M. The largest seller was Point72 Asset Management, cutting an estimated $51.8M.

  • 231 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2023, up from 197 in Q1 2023.
  • Funds reported $2.61B of Axsome Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
  • 50 funds opened new Axsome Therapeutics positions in Q2 2023 and 16 closed out, a net change of +34 holders.
  • The largest Axsome Therapeutics buyer in Q2 2023 was RA Capital Management, an estimated $73.8M added.
  • The largest Axsome Therapeutics seller in Q2 2023 was Point72 Asset Management, an estimated $51.8M sold.

Based on aggregated 13F filings for Q2 2023.